Adaptive Pathways and Patient AccessAn issue panel entitled Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? was held and moderated by Jacoline Bouvy, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK. Jacoline
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) opened last Monday its 19th Annual European Congress in Vienna, Austria with a plenary session entitled What Synergies Could Be Created Between Regulatory and Health Technology Assessments?The plenary discussion was moderated by
Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016 Update on Lung Cancers, plus selected highlights in other tumours Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA NSCLC AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II
Why is the World of Orphan Haemato-Oncology Agents Changing?As an increasing number of targeted oncology and haematology products are getting approved by EMA and FDA, the orphan space is becoming more and more crowded in these therapeutic areas.Patients with a
Kinesys Consulting Ltd is pleased to announce that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to SGX301(synthetic hypericin) for the treatment of
